Reviewing the Scheduling of Approved Products Containing a Combination of Buprenorphine and Naloxone
Section 209 · Sec. 209 ·
What this chapter is about
This part orders a review of how one drug pair is listed. The pair treats addiction. The Secretary must look at the data. If it fits, the Secretary asks the Attorney General to start a rule change.
The document says “shall”Who acts: Secretary of Health and Human ServicesHow: statuteSec. 209 in the PDF
What the document says
“review the relevant data pertaining to the scheduling of products containing a combination of buprenorphine and naloxone that have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355)”
The section directs the Secretary to review, consistent with sections 201 and 202 of the Controlled Substances Act, the data on the scheduling of approved products combining buprenorphine and naloxone.
What the document actually says
“review the relevant data pertaining to the scheduling of products containing a combination of buprenorphine and naloxone that have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355)”
That sentence, in plain words
The Secretary must look at the data. The data is about how these drugs are listed. The drugs mix buprenorphine and naloxone.
What this is about
Federal law sorts controlled drugs into lists called schedules. The list a drug is on sets how tightly it is held. This pair of drugs is used to treat addiction.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.
The document says “shall”Who acts: Secretary of Health and Human ServicesHow: statuteSec. 209 in the PDF
What the document says
“if appropriate, request that the Attorney General initiate rulemaking proceedings to revise the schedules accordingly with respect to such products.”
The section directs the Secretary, if appropriate, to request that the Attorney General begin rulemaking to revise the schedules for those products.
What the document actually says
“if appropriate, request that the Attorney General initiate rulemaking proceedings to revise the schedules accordingly with respect to such products.”
That sentence, in plain words
If the data supports it, the Secretary must ask. The ask goes to the Attorney General. It asks for a rule change on how these drugs are listed.
What this is about
Rulemaking is how an agency writes a rule. It puts out a notice. It takes comments. Only the Attorney General can start it here.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.
The document says “shall”Who acts: Attorney GeneralHow: statuteSec. 209 in the PDF
What the document says
“The Attorney General shall review any request made by the Secretary of Health and Human Services under subsection (a)(2) and determine whether to initiate proceedings to revise the schedules in accordance with the criteria set forth in sections 201 and 202 of the Controlled Substances Act (21 U.S.C. 811, 812).”
The section requires the Attorney General to review any request made under subsection (a)(2) and to decide whether to begin proceedings to revise the schedules, using the criteria in sections 201 and 202 of the Controlled Substances Act.
What the document actually says
“The Attorney General shall review any request made by the Secretary of Health and Human Services under subsection (a)(2) and determine whether to initiate proceedings to revise the schedules in accordance with the criteria set forth in sections 201 and 202 of the Controlled Substances Act (21 U.S.C. 811, 812).”
That sentence, in plain words
The Attorney General must read the request. Then the Attorney General decides whether to start. The tests to use are set out in an older law.
What this is about
The law makes the review required but not the outcome. The Attorney General must decide. The answer can be no.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.
Reauthorize certain programs that provide for opioid use disorder prevention, treatment, and recovery, Public Law 119-44, sec. 209, 139 Stat. 682 (2025). https://www.govinfo.gov/content/pkg/PLAW-119publ44/html/PLAW-119publ44.htm
This page
“Reviewing the Scheduling of Approved Products Containing a Combination of Buprenorphine and Naloxone,” Reauthorize certain programs that provide for opioid use disorder prevention, treatment, and recovery, section 209. Read the Mandate, https://readthemandate.org/pl-119-44/section-209/ (retrieved August 26, 2026).
Cite the document when the claim is about what the document says. Cite this page when the indexing, the wording or the record of what has happened is what is being relied on.
What This Page Covers, and What It Leaves Out
The three things the section requires: the review of data by the Secretary, the request the Secretary may make to the Attorney General, and the Attorney General's own review of that request.
Nothing. The section has two subsections and both are recorded here.
The section refers to sections 201 and 202 of the Controlled Substances Act and to section 505 of the Federal Food, Drug, and Cosmetic Act. None is indexed here, so nothing is recorded about how a drug is scheduled or approved under them.
